CAC
APYX icon

Cowen and Company’s Apyx Medical APYX Stock Holding History

Cowen and Company’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,775,793
Closed -$5.11M – 586
2023
Q1 		$5.11M Hold
1,775,793
– – 0.6% 40
2022
Q4 		$4.16M Sell
1,775,793
-1,079,048
-38% -$3.29M 0.43% 36
2022
Q3 		$12.8M Buy
2,854,841
+36,500
+1% +$261K 1.23% 24
2022
Q2 		$16.5M Buy
2,818,341
+184,338
+7% +$946K 1.59% 20
2022
Q1 		$17.2M Buy
2,634,003
+732,000
+38% +$7.21M 1.66% 13
2021
Q4 		$24.4M Buy
1,902,003
+23,000
+1% +$322K 2.21% 10
2021
Q3 		$26M Buy
1,879,003
+325,804
+21% +$3.43M 1.23% 17
2021
Q2 		$16M Buy
1,553,199
+1,031,157
+198% +$10.2M 0.84% 19
2021
Q1 		$5.04M Buy
522,042
+18,961
+4% +$190K 0.35% 31
2020
Q4 		$3.62M Buy
503,081
+18,835
+4% +$125K 0.32% 34
2020
Q3 		$2.28M Buy
484,246
+30,948
+7% +$153K 0.37% 46
2020
Q2 		$2.52M Buy
453,298
+98,419
+28% +$409K 0.42% 44
2020
Q1 		$1.27M Buy
354,879
+118,893
+50% +$798K 0.29% 74
2019
Q4 		$2M Buy
+235,986
New +$1.7M 0.17% 57

Other funds holding APYX

ACM
Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $4.41B AUM 90.53% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return

Cowen and Company's APYX Position: Q2 2023 in Review

Cowen and Company sold out of Apyx Medical (APYX) in Q2 2023, closing a stake of 1,775,793 shares — an estimated $5.11M sold.

Cowen and Company first reported a position in APYX in Q4 2019 and held it in 14 quarters. The position peaked at $26M in Q3 2021. 56 funds tracked by Wall St. Rank hold APYX as of Q2 2023.

  • Cowen and Company reported no remaining Apyx Medical position as of Q2 2023 after selling out during the quarter.
  • Cowen and Company sold 1,775,793 Apyx Medical shares in Q2 2023, an estimated $5.11M.
  • Cowen and Company first reported a position in Apyx Medical in Q4 2019 and held it in 14 quarters.
  • Cowen and Company's Apyx Medical position peaked at $26M in Q3 2021.
  • 56 funds tracked by Wall St. Rank held Apyx Medical as of Q2 2023.

Based on Cowen and Company's 13F filing for Q2 2023, filed 7 Aug 2023.